Crescent Biopharma, Inc. (CBIO)
CBIO moved a median of -1.24% 30 minutes after news, and -3.98% by the close. How CBIO actually reacts to news — the realized, point-in-time move the market made, measured across 51 labeled events over the last three years with zero look-ahead.
CBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -1.18% | 36% | 11 |
| 30-min | -1.24% | 50% | 12 |
| 60-min | -1.27% | 42% | 12 |
| to close | -3.98% | 25% | 12 |
| Middle 50% of CBIO reactions | -2.93% to +8.40% |
|---|---|
| Median reaction (30-min) | -1.24% |
| Measured reactions | 51 |
Half of all Crescent Biopharma, Inc. news events land between -2.93% and +8.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | -2.44% | 39% | -4.62% |
| Rating reiterations | 11 | +0.48% | 64% | -0.73% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CBIO ranks against every other measured name →
That’s how CBIO usually reacts — get an email when it moves on news →Email me when CBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CBIO's baseline. Nothing else.
Recent CBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Comb | Press release | GlobeNewswire | -1.38% | -6.99% | |
| Crescent Biopharma Announces Grants of Inducement Awards | Press release | GlobeNewswire | -1.52% | +0.15% | |
| Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors | Press release | GlobeNewswire | -1.39% | -3.33% | |
| Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer | Press release | GlobeNewswire | +3.35% | -2.65% | |
| Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million | Press release | GlobeNewswire | — | +14.87% | |
| Form 8-K/A GYRE THERAPEUTICS, INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K/A GYRE THERAPEUTICS, INC. For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form RW GYRE THERAPEUTICS, INC. | SEC filing · Form RW | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form D GYRE THERAPEUTICS, INC. | SEC filing · Form D | SEC EDGAR | — | — | |
| Form S-3 GYRE THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-8 GYRE THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split | Press release | GlobeNewswire | -1.67% | -5.32% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form EFFECT CATALYST BIOSCIENCES, | SEC filing · Form EFFECT | SEC EDGAR | -1.18% | -9.76% | |
| Form 8-K CATALYST BIOSCIENCES, For: Oct 26 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -9.76% | |
| Form 10-Q CATALYST BIOSCIENCES, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | -0.91% | |
| Form S-3/A CATALYST BIOSCIENCES, | SEC filing · Form S-3 | SEC EDGAR | +2.95% | +21.25% | |
| Form 8-K CATALYST BIOSCIENCES, For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | -0.85% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CBIO section they belong to.
Where else CBIO is measured.
CBIO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EASTON PHARMS INC (EAPH) | 52 | 0.00% | 34% |
| VBI Vaccines, Inc. - Ordinary Shares (VBIV) | 52 | -0.01% | 40% |
| Careview Communications, Inc. (CRVW) | 51 | 0.00% | 12% |
| LIMITLESS VENTURE GRP INC (LVGI) | 51 | 0.00% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Crescent Biopharma, Inc.'s median reaction calculated?
Every labeled CBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 51 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.